Cytek Biosciences Inc CTKB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year
Cytek Biosciences Reports Third Quarter 2026 Financial Results
Cytek Biosciences to Participate in Upcoming Investor Conferences
Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS
Cytek Biosciences to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $5.40
- Day Range
- $5.35–5.64
- 52-Week Range
- $3.32–6.33
- Bid/Ask
- $5.59 / $5.64
- Shares Outstanding
- 130.78M
- Market Cap
- $703.62M
- Volume/Avg
- 19,097 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.36
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 703
- Website
- https://www.cytekbio.com
Valuation
Metric | CTKB |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.20 |
Price/Sales | 3.36 |
Price/Cash Flow | — |
Price/Earnings
CTKB
Financial Strength
Metric | CTKB |
|---|---|
Quick Ratio | 3.73 |
Current Ratio | 4.46 |
Interest Coverage | −552.40 |
Quick Ratio
CTKB
Profitability
Metric | CTKB |
|---|---|
Return on Assets (Normalized) | −15.03% |
Return on Equity (Normalized) | −20.43% |
Return on Invested Capital (Normalized) | −19.64% |
Return on Assets
CTKB
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|jXB#wn | LOCK|rwY^Z | $197B | |||
| Medtronic PLC MDT | LOCK|m$b<hr | LOCK|Y^>&& | $134B | |||
| Stryker Corp SYK | LOCK|rSghgkSw | LOCK|&^ | $128B | |||
| Boston Scientific Corp BSX | LOCK|t^%!bW | LOCK|X&WR< | $65B | |||
| Edwards Lifesciences Corp EW | LOCK|p$zHFRHR | LOCK|$^m& | $58B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|!M%s%^B | LOCK|lx | $38B | |||
| DexCom Inc DXCM | LOCK|kDTpG<# | LOCK|<nw@ | $31B | |||
| Koninklijke Philips NV ADR PHG | LOCK|BYS | LOCK|^Qc | $30B | |||
| Steris PLC STE | LOCK|&tl@%k | LOCK|B%MV | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|$T^ch%^ | LOCK|!B | $20B |
United States